Skip to content
Forensic Analysis · Medical Devices · as of Nov 9, 2026

Mimedx Group, Inc. (MDXG)

A forensic read on Mimedx Group, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective
Forensic grade
Safe
Financial health
8.1
Distress distance
Clean
Earnings quality
1
Forensic signals
21.6%
ROE
20.0%
Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Mimedx Group, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 8.1, placing it in the Safe zone. 1 forensic signal was flagged in its latest SEC filings, led by shareholder returns — halted.

What the filings flag

stopped
FY2023→FY2025
Shareholder returns — halted. Capital returns have STOPPED — $10M of buybacks + dividends in FY2023, but ~$0 in FY2025. A halt usually means the company is conserving cash.

Key fundamentals

Latest Revenue$418.6M
Revenue Growth YoY+20.0%
Revenue CAGR (2yr)+14.1%
Net Margin11.6%
Return on Equity21.6%
Debt / Equity0.07x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Mimedx Group, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.